The richer nations of the world have spent huge sums of money over many years to try to improve health outcomes due to extreme poverty – an estimated £1.1 trillion pounds has been spent on development aid over the last five decades, but many have questioned what, …

A recurring theme in recent issues of Trends in Urology & Men’s Health has been the importance of avoiding medical errors and the possible implications of failing to do this. Like all professionals, healthcare professionals may be sued, and in medicine it seems increasingly likely …

Members of Parliament are now preparing to debate the Assisted Dying Bill championed by Rob Marris in early September. It is based on Charles Falconer’s bill that made unprecedented progress through the House of Lords, only to run out of time before the general election. …

It is relatively well established that the incidence of prostate cancer among black men is higher when compared with white men, and this is not explained by the availability of PSA screening.1,2 Evidence is emerging to suggest that black men are more likely than white men …

No surgeon goes to work intending to harm his or her patients. Unfortunately, clinical errors with resultant harm to a patient will occasionally happen. Nowadays, when a serious mistake does occur, the implications for the surgeon can be extremely serious: investigation, suspension, litigation, prosecution and …

There has been some welcome focus in this publication over recent months on high-profile examples of medical error, the role of our professional bodies in investigating them, and the potential consequences for the health professionals involved.
There is less focus on medical errors that occur in …

I would be surprised to find anyone who has not heard of testicular cancer. It is the cancer of young men and should be regularly searched for by testicular self-examination – a process that has been shown on breakfast TV and supported through campaigns in …

Systemic therapy for metastatic prostate cancer has changed radically in the last 10 years with the introduction of several novel agents that have shown significant improvements in progression free and overall survival. The latest major breakthrough is the introduction of a relatively old drug, docetaxel …

9am on Saturday 13 June and we all met outside BAUS HQ at the Royal college of Surgeons in Lincolns Inn Fields, 14 of us cycling to the BAUS annual conference in Manchester to raise money for The Urology Foundation (TUF). A total of 220 …

Your action is required urgently!
 
Most unfortunately, NICE has recently recommended that degarelix should no longer be approved for use in patients presenting acutely with metastatic prostate cancer (a group within its current licensed indication). As a clinician I have often been faced with patients presenting …